2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
06/24/19MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
Continuous Monitoring with Wearable Device Detected Distinct Pulse Wave Patterns in Obstructive Hypertrophic Cardiomyopathy Patients as Compared to Healthy Volunteers SOUTH SAN FRANCISCO, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive Hypertrophic Cardiomyopathy (oHCM) Using a Wearable Biosensor,” in the Nature Partner Journal, Digital Medicine. This research is part of M... 
06/18/19MyoKardia to Present at 2019 BMO Prescriptions for Success Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Jake Bauer, Chief Business Officer, will participate in a fireside chat at the 2019 BMO Prescriptions for Success Healthcare Conference on Tuesday, June 25th, 2019, at 1:20 p.m. ET in New York, NY. A webcast of the presentation will be avail... 
05/28/19MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable Heart Failure with Reduced Ejection Fraction Anticipated in Second Half 2019 SOUTH SAN FRANCISCO, Calif. and ATHENS, Greece, May 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc., (Nasdaq: MYOK), presented data today at the European Society of Cardiology Heart Failure Congress from its Phase 1a single... 
05/09/19MyoKardia Reports First Quarter 2019 Financial Results
Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the quarter ended March 31, 2019. “With a strong first quarter behind us, Myo... 
05/08/19MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15th, 2019, at 8:40 a.m. PT (11:40 a.m. ET) in Las Vegas, NV. A webcast of the ... 
05/07/19MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
Three Researchers Awarded $250,000 Each to Advance Independent Research in Cardiac Diseases SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced the award of $750,000 divided among three innovative research projects through the first cycle of its MyoSeeds™ Research Grants Program (“MyoSeeds”).  MyoSeeds is MyoKardia’s initiative int... 
05/02/19MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it will report first quarter 2019 financial and operating results on Thursday, May 9, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).  ... 
04/30/19Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal MedicineMavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for which No Targeted Medical Therapies Exist Twelve-week Treatment with Mavacamten Demonstrated Reductions in Obstruction and Improvements in Patient Symptoms and Function Learnings from Phase 2 Trial Informed and Guided Design of the Current Pha... 
03/26/19MyoKardia Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 4,925,000 shares of its common stock at a public offering price of $51.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional ... 
03/25/19MyoKardia Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering to sell $200,000,000 in shares of its common stock. MyoKardia expects to grant the underwriters a 30-day option to purchase up to $30,000,000 in additional shares of common stock at the p... 
03/06/19MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the Cowen & Co. 39th Annual Health Care Conference on Wednesday, March 13th, 2019, at 10:40 a.m. ET in Boston, MA. A webcast of the presentation will be available by visiting the Investor... 
03/04/19MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers Suggest Potential for Mavacamten to Slow or Reverse Disease Progression Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT); Data Presentation at American College of Cardiology on Sunday, March 17, 2019 SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYO... 
02/28/19MyoKardia Reports Fourth Quarter and Full Year 2018 Financial Results
Company to Host Conference Call and Webcast on March 4, 2019 at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018.  “2018 was MyoKardia’s most significant year of progress towards building ... 
01/23/19MyoKardia Appoints William Fairey as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of William C. Fairey as Chief Commercial Officer and Executive Vice President.  Mr. Fairey will have global responsibility for oversight of all aspects of commercial operations and serve as a key member of MyoKardia’s executive lea... 
01/03/19MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th, 2019, at 8:30 a.m. PT (11:30 a.m. ET) in San Francisco. A webcast of the presentation will be available by visiting the Invest... 
01/02/19MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
Management to Host Conference Call at 8:30 a.m. ET/5:30 a.m. PT SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on...